164 related articles for article (PubMed ID: 24940965)
1. A benzisothiazole derivative and antipsychotic agent, perospirone, for augmentation of selective serotonin reuptake inhibitors (SSRIs) in refractory obsessive-compulsive disorder (OCD): two patient case series.
Matsunaga H; Matsui T; Ohya K; Okino K; Hayashida K; Maebayashi K; Kiriike N; Stein DJ
Int J Psychiatry Clin Pract; 2006; 10(2):142-5. PubMed ID: 24940965
[TBL] [Abstract][Full Text] [Related]
2. Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression.
Otsuka T; Togo T; Sugiyama N; Uehara K; Yoshimi A; Karashima A; Shioya H; Hirayasu Y
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):564-6. PubMed ID: 17166643
[TBL] [Abstract][Full Text] [Related]
3. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
[TBL] [Abstract][Full Text] [Related]
4. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
Pallanti S; Bernardi S; Antonini S; Singh N; Hollander E
CNS Drugs; 2009 Dec; 23(12):1047-55. PubMed ID: 19958042
[TBL] [Abstract][Full Text] [Related]
7. [Is it time for revision of the section on obsessive-compulsive disorder in the Guideline on Anxiety Disorders?].
van Ingen Schenau WJ; Wisman PW
Tijdschr Psychiatr; 2007; 49(5):315-25. PubMed ID: 17492582
[TBL] [Abstract][Full Text] [Related]
8. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of 5-hydroxytryptamine-3 (5-HT3) receptor antagonists in augmentation with selective serotonin reuptake inhibitors (SSRIs) in the treatment of moderate to severe obsessive-compulsive disorder: a systematic review and meta-analysis of randomized clinical trials.
Eissazade N; Mosavari H; Eghdami S; Boroon M; Ashrafi F; Shalbafan M
Sci Rep; 2023 Nov; 13(1):20837. PubMed ID: 38012263
[TBL] [Abstract][Full Text] [Related]
10. Repetitive transcranial magnetic stimulation (rTMS) augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant obsessive-compulsive disorder (OCD): a meta-analysis of randomized controlled trials.
Ma ZR; Shi LJ
Int J Clin Exp Med; 2014; 7(12):4897-905. PubMed ID: 25663986
[TBL] [Abstract][Full Text] [Related]
11. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
Sun TF; Lin PY; Wu CK
Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic treatment in obsessive-compulsive disorder: a literature review.
Keuneman RJ; Pokos V; Weerasundera R; Castle DJ
Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder.
Sato Y; Yasui-Furukori N; Nakagami T; Saito M; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Apr; 33(3):416-8. PubMed ID: 19166896
[TBL] [Abstract][Full Text] [Related]
14. New treatment options for OCD.
Fineberg NA
Int J Psychiatry Clin Pract; 2007; 11 Suppl 2():24-30. PubMed ID: 24926869
[TBL] [Abstract][Full Text] [Related]
15. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
McDougle CJ; Price LH; Goodman WK; Charney DS; Heninger GR
J Clin Psychopharmacol; 1991 Jun; 11(3):175-84. PubMed ID: 1820757
[TBL] [Abstract][Full Text] [Related]
16. Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder.
Vakili Y; Gharaee B; Habibi M
Iran J Psychiatry Behav Sci; 2015 Jun; 9(2):e845. PubMed ID: 26288647
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic augmentation in the treatment of obsessive-compulsive disorder.
Thamby A; Jaisoorya TS
Indian J Psychiatry; 2019 Jan; 61(Suppl 1):S51-S57. PubMed ID: 30745677
[TBL] [Abstract][Full Text] [Related]
18. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
Del Casale A; Sorice S; Padovano A; Simmaco M; Ferracuti S; Lamis DA; Rapinesi C; Sani G; Girardi P; Kotzalidis GD; Pompili M
Curr Neuropharmacol; 2019; 17(8):710-736. PubMed ID: 30101713
[TBL] [Abstract][Full Text] [Related]
19. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.
Bloch MH; Storch EA
J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):251-62. PubMed ID: 25791142
[TBL] [Abstract][Full Text] [Related]
20. [Value of fluoxetine in obsessive-compulsive disorder in the adult: review of the literature].
Etain B; Bonnet-Perrin E
Encephale; 2001; 27(3):280-9. PubMed ID: 11488259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
